Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer
This is an open-label, randomized trial, it compares the efficacy and safety between apatinib combined chemotheray and chemotherapy for adjuvant treatment of esophageal cancer
Esophageal Cancer
DRUG: Docetaxel|DRUG: Nedaplatin|DRUG: Endostar
3 year disease-free survival rate, the percentage of the patients whose disease cannot be detected after curative therapy in three years, 3 years
overall survival, From the time of randomization to the time of death for any reason., 3 years
This is an open-label, randomized trial, it compares the efficacy and safety between apatinib combined chemotheray and chemotherapy for adjuvant treatment of esophageal cancer